Takeda, a leading Japanese pharmaceutical company, has commenced construction on a $230 million expansion of its Los Angeles production facility. This development marks the largest plasma fractionation site for Takeda worldwide and is expected to increase annual production by two million liters.
The expansion will involve repurposing an existing building and utilizing current site infrastructure, resulting in reduced planning and permitting time typically associated with new construction. In addition to streamlining the process, this approach aligns with Takeda’s commitment to minimizing environmental impact through responsible resource management and waste reduction.
According to Thomas Wozniewski, Global Manufacturing & Supply Officer at Takeda, the United States plays a critical role in their global manufacturing network and contributes significantly to supply chain resilience. The increased capacity at their LA facility will enable them to produce more plasma-derived therapies for patients in need.
This update was originally published on Connect CRE website.
